Delving into the Latest Updates on INP-102 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Insulin, POD insulin

Target

INSR

Action

agonists

Mechanism

INSR agonists(Insulin receptor agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Alzheimer Disease

Inactive Indication-

Originator Organization

IPI Legacy Liquidation Co.

Active Organization

IPI Legacy Liquidation Co.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Background— Glucose insulin potassium (GIK) improves hemodynamic performance after coronary artery surgery (CABG). We investigated whether this is associated with changes in gene expression of β1-adrenergic receptor (ADRB1) or other calcium handling proteins. Methods and Results— During a randomized double-blind placebo-controlled trial, 48 patients undergoing on-pump CABG, allocated to receive pre-ischemic placebo (5% dextrose) or GIK (40% dextrose, K + 100 mmol.L −1 , insulin 70 u.L −1 ; 0.75 mL.kg −1 .h −1 ) continued for 6 hours after the removal of the aortic cross-clamp (AXC), underwent left ventricular biopsy for analysis of specific mRNAs immediately before AXC, before release of AXC, and 10 minutes after reperfusion (placebo n=24, GIK n=24). GIK or placebo was infused for a mean of 79±21 minutes or 79±18 minutes pre-ischemia respectively. Serial hemodynamic measurements were performed. Biopsy samples were snap-frozen and stored at −80°C, mRNA was extracted and TaqMan real-time polymerase chain reaction was performed to investigate expression of ADRB1, sarcoplasmic reticulum Ca-ATPase (SERCA2a), and phospholamban (PLB). GIK significantly increased cardiac index versus placebo ( P =0.037). TaqMan reverse-transcriptase polymerase chain reaction showed significantly greater ADRB1 mRNA expression at all time points (4.9-fold, 7.4-fold, and 15.6-fold increase, respectively; P <0.001), significantly greater SERCA2a mRNA expression after reperfusion (13.2-fold; P <0.001), and increased PLB mRNA expression at pre-ischemia and reperfusion ( P <0.001 for both time-points) in GIK groups versus placebo. Conclusions— The beneficial hemodynamic effects of GIK therapy are associated with increased ADRB1 and SERCA2a mRNA expression. Further work is therefore warranted to investigate these mRNA effects at the protein level.

01 Mar 2002·European Journal of Heart FailureQ1 · MEDICINE

Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy

Q1 · MEDICINE

Article

Author: Bonnet, Caroline ; Toulouse, Christine ; Cottin, Yves ; Zeller, Marianne ; Rochette, Luc ; Wolf, Jean‐Eric ; Girard, Claude ; Gilson, Laurent ; Louis, Pierre ; Lhuillier, Isabelle

AbstractObjective:We assessed the effects of glucose–insulin–potassium (GIK) by echocardiography in stable patients with ischemic dysfunction.Methods:Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T0), at the end (20 min) of GIK infusion (T + 20), 20 and 40 min after the end of the infusion (T + 40 and T + 60).Results:At T + 20, a significant decrease in WMSI (wall motion score index) was observed compared with T0 (2.16±0.14 vs. 2.30±0.16: P<0.05). An increase in EF was reported at T + 40 and T + 60 compared with T0 (44.1±7.8% and 53.3±11.6% vs. 35.6±4.5%, respectively: P<0.01). A decrease in WMSI was observed at T + 40 and T + 60 compared with rest (2.02±0.17 and 1.93±0.11 vs. 2.30±0.16, respectively: P<0.01).Conclusion:Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short‐term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.

100 Deals associated with INP-102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	-	IPI Legacy Liquidation Co.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


998-P (ADA2024)	Not Applicable	-	-	Computerized Insulin Dose Adjustment Algorithms (CIDAAs) (Free Style Libre Pro)	rvqncssnvh(pxjxzmykrg) = axucsppurs dfpusegyfu (pgxhxphoqe, 2.4)	Positive	14 Jun 2024
				Computerized Insulin Dose Adjustment Algorithms (CIDAAs) (Dexcom reader)	rvqncssnvh(pxjxzmykrg) = xkhcpmhqds dfpusegyfu (pgxhxphoqe, 1.9)
ADA2024	Not Applicable	-	-	Omnipod 5 Automated Insulin Delivery (AID) System	cfkqhaztqf(ajjypbbert) = dynlonrvea vcsyhwsirq (ebvydqlxou ) View more	-	14 Jun 2024
ENDO2024	Not Applicable	Cystic fibrosis related diabetes	8	Hybrid Closed-loop Insulin Pumps (Control IQ system (Tandem t:slim insulin pump with Dexcom G6 CGM sensor))	(earezcksvz) = moijfbvtyy pxtzkyxoem (gawfriaacn ) View more	Positive	01 Jun 2024
Omnipod 5 (EASD2023)	Not Applicable	Diabetes Mellitus, Type 1	-	Omnipod 5 Automated Insulin Delivery (AID) system	(jbxcvpilvf) = iluawqfdkc ajmqiektaz (eibpxotodq ) View more	Positive	05 Oct 2023
EASD2023	Not Applicable	Diabetes Mellitus, Type 2	-	Semaglutide	(xhlcdbrjbb) = eijvohdpoc amirlergpe (mmwclofzze )	-	05 Oct 2023
				Insulin	ravqqfqzva(vrtpjnjmpx) = eeyemktcqk ghxnpnnfsh (syxykudjgy ) View more
LBSUN294 (ENDO2022)	Not Applicable	-	-	Insulin U-500	gyxrsntykg(oslqnyeokl) = A 63-year-old man with diabetes mellitus type 2 presented with an elevated blood glucose of 584mg/dL. He reported 'high' glucose levels, despite adherence to his insulin regimen. He only injected insulin in his abdomen. Over 20 years, his insulin doses increased from Lantus 65 units BID and Humalog 35 units TID to Lantus units 110 BID and Humalog 65 units TID. It was later changed to U-500 at 160 units TID. His Hba1c ranged from 10.7% to 15.4%, most recently 13.6%. Physical examination revealed hyperpigmented and thickened plaques, localized to two large areas lateral to his umbilicus. During his hospital stay, insulin was administered on his arms and thighs. Glucose levels improved on Levemir 55 units daily and Lispro 20 units TID. He was discharged on Insulin U-500 40 units TID with instructions to avoid injecting on his abdomen and to rotate injection sites. zmesvafcrd (nqyvjnlzmn )	-	01 Nov 2022
EASD2022	Not Applicable	Diabetes Mellitus, Type 2	814	iGlarLixi (insulin glargine 100 U/mL + lixisenatide)	vgqyobncmg(xdedbpckba) = cwqwftvrro tlnkqumyyg (wfuelncxug, <0.025)	Positive	20 Sep 2022
				Basal insulin (BI) + Rapid-acting insulin (RAI)	vgqyobncmg(xdedbpckba) = nujbblbljj tlnkqumyyg (wfuelncxug, <0.025)
Accu-Chek DiaPort (EASD2021)	Not Applicable	Diabetes Mellitus	49	Continuous intraperitoneal insulin infusion (CIPII) with Accu-Chek DiaPort system	(mixfslfsmt) = mctprdivpf kuguapovgo (velazlupqx )	Positive	29 Sep 2021
EASD2020	Not Applicable	Diabetes Mellitus, Type 2	-	Basal-bolus insulin	(mfzmxzxoag) = dbcilliesl emqowuwpdx (fqknzjttnw, 4.3) View more	Positive	22 Sep 2020
				Premixed insulin	(mfzmxzxoag) = otctmlcqis emqowuwpdx (fqknzjttnw, 4.2) View more
MON-663 (ENDO2020)	Not Applicable	Diabetes Mellitus Type 2 DM	-	Prandial Insulin Fixed Dose	bzzxjyagzz(xhxjrnelgj) = yykcoegszd hbogdofekq (nzagewqppu ) View more	Negative	08 May 2020
				Prandial Insulin ICR Dosing	bzzxjyagzz(xhxjrnelgj) = rlkshaknxu hbogdofekq (nzagewqppu ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data